Eleftherios Mylonakis

Papers

Total Citations

254

H-Index

About

Eleftherios Mylonakis is a pioneering physician-scientist whose work bridges infectious disease, clinical microbiology, and innovative drug discovery. His research focuses on antimicrobial resistance, host-pathogen interactions, and the development of novel diagnostic and therapeutic platforms. A major contribution is the creation of a whole-animal automated platform using *Caenorhabditis elegans* to screen for compounds against multi-drug resistant *Staphylococcus aureus*—a breakthrough that has garnered nearly 100 citations and transformed early-stage drug discovery. During the COVID-19 pandemic, Mylonakis led a seminal review on emerging technologies for diagnosis and treatment, cited over 155 times, which provided critical guidance for resource-limited healthcare systems. His work is distinguished by its translational impact, combining high-throughput screening with in vivo models to accelerate the pipeline from lab to clinic. With hundreds of publications and a career marked by innovation in infectious disease research, Mylonakis continues to shape how we understand, detect, and treat resistant pathogens, making him a leading voice in the fight against global antimicrobial resistance.